Bell Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-53,202
Closed -$3.86M 65
2025
Q1
$3.86M Sell
53,202
-930
-2% -$66.6K 0.71% 63
2024
Q4
$4.01M Sell
54,132
-43,195
-44% -$3.02M 0.73% 60
2024
Q3
$6.42M Sell
97,327
-5,555
-5% -$404K 1.18% 36
2024
Q2
$9.5M Sell
102,882
-24,458
-19% -$2.17M 1.33% 25
2024
Q1
$12.2M Sell
127,340
-49,017
-28% -$4.12M 1.78% 14
2023
Q4
$13.4M Buy
176,357
+49,314
+39% +$3.43M 2.05% 6
2023
Q3
$8.8M Buy
127,043
+40,578
+47% +$3.26M 1.45% 30
2023
Q2
$8.16M Sell
86,465
-14,196
-14% -$1.23M 1.4% 39
2023
Q1
$8.33M Buy
100,661
+10,688
+12% +$840K 1.52% 28
2022
Q4
$6.71M Buy
89,973
+24,741
+38% +$1.91M 1.26% 43
2022
Q3
$5.39M Sell
65,232
-783
-1% -$75.3K 1.09% 50
2022
Q2
$6.28M Buy
66,015
+2,788
+4% +$289K 1.24% 47
2022
Q1
$7.44M Buy
63,227
+8,343
+15% +$936K 1.28% 41
2021
Q4
$7.11M Buy
54,884
+262
+0.5% +$30.6K 1.15% 48
2021
Q3
$6.18M Buy
54,622
+2,049
+4% +$234K 1.05% 52
2021
Q2
$5.45M Sell
52,573
-229
-0.4% -$21.6K 1.07% 51
2021
Q1
$4.42M Buy
+52,802
New +$4.46M 0.95% 55

Other funds holding EW

Bell Asset Management's EW Position: Q2 2025 in Review

Bell Asset Management sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 53,202 shares — an estimated $3.86M sold.

Bell Asset Management first reported a position in EW in Q1 2021 and held it in 17 quarters. The position peaked at $13.4M in Q4 2023. 1,260 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Bell Asset Management reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
  • Bell Asset Management sold 53,202 Edwards Lifesciences shares in Q2 2025, an estimated $3.86M.
  • Bell Asset Management first reported a position in Edwards Lifesciences in Q1 2021 and held it in 17 quarters.
  • Bell Asset Management's Edwards Lifesciences position peaked at $13.4M in Q4 2023.
  • 1,260 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Bell Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.